A comprehensive view of Cardiovascular / Heart Health. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.
Executive Perspective: AstraZeneca CEO Pascal Soriot defends recent spate of acquisitions, arguing they're vital for future growth; Soriot says the deals aim to create synergy between oncology, vaccines, and respiratory disease products
Published:
April 25, 2024
by FiercePharma
|
Merck's newly approved PAH treatment, Winrevair, forecast to reach sales of US$3.9B by 2029; the robust start to the drug's launch signals a significant boost for the company's future revenue with cancer drug Keytruda's patent expiry looming
Published:
April 25, 2024
by FiercePharma
|
BRISTOL MYERS SQUIBB CO - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Published:
April 25, 2024
by SEC Edgar Filings
|
AstraZeneca reports Q1 revenue up 17% year-over-year to US$12.7B, operating profit up 22% to US$3.1B, with oncology sales growing 23% YoY to US$5.1B, metabolic and cardiovascular drug sales increasing 20% YoY to US$3.1B; annual guidance remains unchanged
Published:
April 25, 2024
by BioPharma Dive
|
Boston Scientific announces results for first quarter 2024
Published:
April 24, 2024
by Boston Scientific Corp.
|
Ask us about our Tissue & Hygiene market view